Form 4: Nurix Therapeutics Director Roy D. Baynes Granted Stock Options

Director Roy D. Baynes of Nurix Therapeutics, Inc. was granted stock options to purchase 50,000 shares of common stock on March 11, 2025.

Summary

• Roy D. Baynes, a director of Nurix Therapeutics, Inc., was granted stock options on March 11, 2025.
• The options allow him to purchase 50,000 shares of Nurix Therapeutics common stock at an exercise price of $13.90.
• The options vest monthly, starting April 11, 2025, over a three-year period, fully vesting on March 11, 2028, contingent upon continued service to the company.
• The options expire on March 10, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, particularly at the director level. This aligns the director's compensation with the company's stock performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotech companies.
• The size of the grant (50,000 shares) and the vesting schedule (monthly over three years) are within typical ranges for similar companies.
• Comparable companies like Arcus Biosciences and Gilead Sciences also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates